" class="no-js "lang="en-US"> Amgen Archives - Medtech Alert
Tuesday, February 07, 2023

Sort by:

Date

Top Post

Novalis Biotech Invests in Ultra Sensitive Genomics Technology by Rarity Bioscience

Rarity Bioscience announces a new strategic investment from Belgium-based Novalis Biotech. The investment is facilitated […]

Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

Arrowhead Pharmaceuticals has announced a $25M milestone payment from Amgen. This milestone was triggered by […]

Hundreds of Patients to Benefit From Revolutionary Lung Cancer Drug On The NHS

A revolutionary targeted drug for lung cancer will be made available to anyone who is […]

Owkin and Amgen Use AI to Improve Cardiovascular Risk Prediction

AI startup Owkin and Amgen have announced the results of a three-year project to use […]

Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio

Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The […]

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases

Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for […]

FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]

Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a […]

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and […]

FDA Accepts Amgen's sNDA For Otezla ®

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for […]

  1. Halozyme Appoints Barbara Duncan to its Board of Directors Read more
  2. Dianosic Raises €4.7M to Bring Treatment for Chronic Rhinitis into Clinical Trial Read more
  3. Clexio and Genetika+ Announce Partnership Using Proprietary Antidepressant Screening Platform Read more
  4. Mihir Patel Joins Cambia Health Solutions as Chief Pharmacy Officer Read more
  5. Sandoz Biologics License Application for Proposed Biosimilar Denosumab Accepted by US FDA Read more